Keyzilen fails Phase III TACTT3 trial to treat tinnitus.- Auris Medical.
Auris Medical Holdings provided an update on the TACTT3 clinical trial with Keyzilen in the treatment of acute inner ear tinnitus as well as the results from the Company's Extraordinary General Meeting held on 12 March 2018. Preliminary top-line data from the TACTT3 trial indicate that the study did not meet its primary efficacy endpoint of a statistically significant improvement in the Tinnitus Functional Score from baseline to Day 84 in the active treated group compared to placebo either in the overall population or in the otitis media subpopulation. The Company is investigating the outcomes, including those in the previously conducted sister trial TACTT2, and will provide an update in due course.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins